Cited by 176Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchGenetic Associations and Epidemiology

Association between genetic traits for immune-mediated diseases and Alzheimer disease

Open access
Yokoyama, Jennifer S., Wang, Yunpeng, Schork, Andrew J., Thompson, Wesley K., Karch, Celeste M., Cruchaga, Carlos, McEvoy, Linda K., Witoelar, Aree +21 more·2016·JAMA Neurology

Abstract

IMPORTANCE: Late-onset Alzheimer disease (AD), the most common form of dementia, places a large burden on families and society. Although epidemiological and clinical evidence suggests a relationship between inflammation and AD, their relationship is not well understood and could have implications for treatment and prevention strategies. OBJECTIVE: To determine whether a subset of genes involved with increased risk of inflammation are also associated with increased risk for AD. DESIGN, SETTING, AND PARTICIPANTS: In a genetic epidemiology study conducted in July 2015, we systematically investigated genetic overlap between AD (International Genomics of Alzheimer's Project stage 1) and Crohn disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes, celiac disease, and psoriasis using summary data from genome-wide association studies at multiple academic clinical research centers. P values and odds ratios from genome-wide association studies of more than 100 000 individuals were from previous comparisons of patients vs respective control cohorts. Diagnosis for each disorder was previously established for the parent study using consensus criteria. MAIN OUTCOMES AND MEASURES: The primary outcome was the pleiotropic (conjunction) false discovery rate P value. Follow-up for candidate variants included neuritic plaque and neurofibrillary tangle pathology; longitudinal Alzheimer's Disease Assessment Scale cognitive subscale scores as a measure of cognitive dysfunction (Alzheimer's Disease Neuroimaging Initiative); and gene expression in AD vs control brains (Gene Expression Omnibus data). RESULTS: Eight single-nucleotide polymorphisms (false discovery rate P < .05) were associated with both AD and immune-mediated diseases. Of these, rs2516049 (closest gene HLA-DRB5; conjunction false discovery rate P = .04 for AD and psoriasis, 5.37 × 10-5 for AD, and 6.03 × 10-15 for psoriasis) and rs12570088 (closest gene IPMK; conjunction false discovery rate P = .009 for AD and Crohn disease, P = 5.73 × 10-6 for AD, and 6.57 × 10-5 for Crohn disease) demonstrated the same direction of allelic effect between AD and the immune-mediated diseases. Both rs2516049 and rs12570088 were significantly associated with neurofibrillary tangle pathology (P = .01352 and .03151, respectively); rs2516049 additionally correlated with longitudinal decline on Alzheimer's Disease Assessment Scale cognitive subscale scores (β [SE], 0.405 [0.190]; P = .03). Regarding gene expression, HLA-DRA and IPMK transcript expression was significantly altered in AD brains compared with control brains (HLA-DRA: β [SE], 0.155 [0.024]; P = 1.97 × 10-10; IPMK: β [SE], -0.096 [0.013]; P = 7.57 × 10-13). CONCLUSIONS AND RELEVANCE: Our findings demonstrate genetic overlap between AD and immune-mediated diseases and suggest that immune system processes influence AD pathogenesis and progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2016.0150

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • IPMK is implicated in neurodegeneration, cancer, and inflammation.

    “Over two decades, multidisciplinary research has unveiled its far-reaching biological roles and implications in diverse diseases, including neurodegeneration, cancer, and inflammation.”

    From From Obscurity to Prominence: IPMK’s Expanding Role in Cellular Signaling, Physiology, and Disease (2025) · cites this paper as [32]

    The Discussion (page not provided) links IPMK to Alzheimer’s and Huntington’s disease and suggests a role in neurodegeneration. It also describes IPMK as an inflammation-associated gene, but the paper does not state that IPMK is implicated in cancer; its discussion of p53-mediated transcription and cell death does not establish that disease claim. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • IPMK is involved in inflammatory disorders, obesity, Alzheimer's disease, inflammatory bowel disease, and intestinal neuroendocrine tumors.

    “Over the past two decades, research utilizing animal models and human mutation analyses has revealed IPMK’s involvement in a wide array of human diseases, including inflammatory disorders [28,29], obesity [30,31], Alzheimer’s disease [32], inflammatory bowel disease [33,34], and intestinal neuroendocrine tumors [35].”
  • The enrichment of prioritized proteins in microglia and immune pathways supports a strong immunological role in AD, including TREM2, CD33, and IL34.

    “supporting a strong immunological role in AD93–95 including TREM27,96, CD33, and IL34.”
  • Overlap in the genetic architecture between AD and other diseases has been reported, including type 2 diabetes and immune-mediated diseases such as Crohn's disease.

    “Overlap in the genetic architecture between AD and other diseases has also been reported, including type 2 diabetes [124] and immune-mediated diseases such as Crohn’s disease [125, 126], although the precise mechanisms underlying this overlap remain to be elucidated.”

    From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [125]

  • Genetic pleiotropy studies have found striking genetic overlap between AD and several autoimmune disorders, including psoriasis and Crohn disease.

    “Although AD is not considered a classical autoimmune disease, genetic pleiotropy studies have found striking genetic overlap between AD and several autoimmune disorders, including psoriasis and Crohn disease (6).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 33 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Yokoyama, J. S., Wang, Y., Schork, A. J., Thompson, W. K., Karch, C. M., Cruchaga, C., McEvoy, L. K., Witoelar, A., Chen, C.-H., Holland, D., Brewer, J. B., Franke, A., Dillon, W. P., Wilson, D. M., Mukherjee, P., Hess, C. P., Miller, Z., Bonham, L. W., Shen, J., Rabinovici, G. D., Rosen, H. J., Miller, B. L., Hyman, B. T., Schellenberg, G. D., Karlsen, T. H., Andreassen, O. A., Dale, A. M., Desikan, R. S., & Initiative, F. T. A. D. N.
Affiliations
  • University of California, San Francisco (US)
  • Washington University in St. Louis (US)
  • University of California San Diego (US)
  • Oslo University Hospital (NO)
  • Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany
  • Massachusetts General Hospital (US)
  • University of Pennsylvania (US)
Corresponding author
Yokoyama, Jennifer S.
Venue
JAMA Neurology
Published
2016-06-01
Volume
73
Issue
6
Pages
691
ISSN
2168-6149 (ISSN-L)
OpenAlex
W2339196082
Cited by
176
References
33
Citations by year
2026: 9 · 2025: 14 · 2024: 15 · 2023: 14 · 2022: 14 · 2021: 25 · 2020: 22 · 2019: 10 · 2018: 23 · 2017: 16 · 2016: 12 · 2015: 1
FWCI
16.37
Type
journal article
Language
en
Open access
Locations
  • JAMA Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institute on Aging (R01AG045611, U24-AG041689-01, K01AG046374, U01AG016976, P50AG005131, P30AG010124, K01AG049152, U01AG032984, P50AG005681, RC2AG036528, K24AG045333, P01AG019724, U24AG041689, U24AG021886, P50AG023501)
  • National Institute on Drug Abuse (RC2DA029475)
  • National Institute of General Medical Sciences (R01GM104400)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD061414)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
late-onset Alzheimer's disease, immune-mediated diseases, genetic overlap, pleiotropy, inflammation, HLA-DRB5, inositol polyphosphate multikinase, neurofibrillary tangles, neuritic plaques, cognitive decline, psoriasis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes, celiac disease, single nucleotide polymorphisms, gene expression
MeSH terms
Alzheimer Disease, Cognition Disorders, Female, Humans, Inflammation, Male, Phosphotransferases (Alcohol Group Acceptor), Polymorphism, Single Nucleotide, Genome-Wide Association Study, HLA-DRB5 Chains

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review